Day: May 6, 2020

Daix (France), May 6, 2020 – Given the COVID-19 situation, and in accordance with the provisions of Order no. 2020-321 of March 25, 2020 adapting the form of meeting and decision-making rules for shareholders’ meetings and governing bodies of legal entities during the pandemic, Inventiva informs its shareholders and the entire financial community that its Combined (Ordinary and Extraordinary) Shareholders Meeting will be a closed meeting, with no shareholders physically present, at 2pm on May 28, 2020 at the Company’s registered office.Terms of disposal of the preparatory documentsDocuments for the Shareholders Meeting will be sent out by email. They can also be obtained upon request from the Company or downloaded from the “Investors/Shareholders Meeting” section of its website at www.inventivapharma.com.Participation modalitiesShareholders...

Daix (France), le 6 mai 2020 – Dans le contexte de la pandémie de COVID-19, et conformément aux dispositions de l’Ordonnance n°2020-321 du 25 mars 2020 portant notamment sur l’adaptation des règles de réunion et de délibération des assemblées et organes dirigeants des personnes morales en raison de la pandémie de COVID-19, Inventiva informe ses actionnaires et l’ensemble de la communauté financière que son Assemblée Générale Mixte (ordinaire et extraordinaire) se tiendra à « huis clos », hors la présence physique des actionnaires, le 28 mai 2020 à 14h au siège social de la Société.Modalités de mise à disposition des documents préparatoiresLes documents relatifs à l’Assemblée Générale sont disponibles par message électronique sur simple demande auprès de la Société, ou peuvent être consultés sur le site internet de la société www.inventivapharma.com,...

Amsterdam, 6 May 2020 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, confirms that all resolutions that were brought up for vote were supported during its Annual General Meeting earlier today.Ms. Deanna Goodwin was re-appointed to the Supervisory Board of Arcadis for a period of four years.As a precautionary measure to protect its cash position in the current COVID-19 situation, the company had already withdrawn the dividend proposal from the agenda of the Annual General Meeting. This was communicated on 26 March 2020.The voting outcome per agenda item will be published on the Arcadis website in the coming days.-End-For further information please contact:Arcadis Investor RelationsJurgen PullensMobile: +31 6 51599483E-mail: jurgen.pullens@arcadis.comArcadis Group CommunicationsJoost...

First Quarter 2020 (1Q20) financial highlightsÍslandsbanki made a loss in 1Q20 of ISK 1.4bn compared to a profit of ISK 2.6bn in 1Q19.Annualised return on equity (after tax) in 1Q20 was -3.0% (1Q19: 5.9%).Net interest income was ISK 8.6bn (1Q19: ISK 7.9bn), an increase of 8.1% between years and the net interest margin was 2.8% (1Q19: 2.7%).Net fee and commission income totalled ISK 2.5bn (1Q19: ISK 2.6bn), down by 5.9% between years.Loan impairment charges and net valuation changes generated a loss of ISK 3,490m in 1Q20, compared to ISK 907m loss in1Q19.Administrative costs dropped by 8.4% between years and totalled ISK 5.7bn (1Q19: ISK 6.2bn).The cost to income ratio for the Group for the period was 62.9% compared to 59.6% for the same period in 2019 while the same ratio for the parent company was 61.5% compared to 58.1% in 1Q19.Loans...

Afkoma fyrsta ársfjórðungs 2020

Medtronic Assurance Program Will Provide Access to Glucose Sensors and Insulin Pump Supplies at No Cost to Eligible U.S. CustomersDUBLIN, May 06, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced an expansion of the Medtronic Assurance program with a new option to support diabetes customers who have lost their health insurance due to COVID-19-related job loss. Current eligible U.S. customers can now receive a 3-month supply of glucose sensors, infusion sets and reservoirs at no cost.This new addition to the Medtronic Assurance program builds on the company’s holistic approach to ensuring that customers have continued access to diabetes technology and supplies. The Medtronic Assurance program has multiple options for customers in need that include flexible payment plans, payment...

PARIS and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, announced results from an interim analysis of findings from QGC001/1QG4, its study of firibastat in end-stage renal failure (ESRD) patients.The interim analysis shows that, because of a slower elimination (longer half-life [t ½ ]), exposure (AUC) to firibastat and its main metabolites is relatively more important in ESRD patients compared to healthy volunteers, without any significant increase in peak concentration (Cmax). Firibastat was well tolerated in the study and no related adverse event was recorded. No significant deterioration...